Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

40.65 -0.47 (-1.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals

< Previous 1 2 3 4 5 6 7 Next >
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Why Ionis Pharmaceuticals Stock Popped Today
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant... 
Via Benzinga
Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action
Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a hereditary disease that prevents... 
Via Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. 
Via Investor's Business Daily
The 7 Most Hated Stocks by Institutional Traders
Discover the surprising stocks institutional traders are selling, and find out what their moves could mean for your portfolio's future. 
Via InvestorPlace
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
Via Benzinga
Ionis Pharmaceuticals's Earnings Outlook
Via Benzinga
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
Via Benzinga
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key  
Via Benzinga
Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday
Keybanc cut the price target for Baxter International Inc. (NYSE: BAX) from $53 to $51. Keybanc analyst Matthew Mishan maintained an Overweight rating. Baxter International shares rose 1.2% to $47.58... 
Via Benzinga
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease
The companies are working on treatments for a leading cause of heart failure. 
Via Investor's Business Daily
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting  
Via Benzinga
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A. 
Via Investor's Business Daily
Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing  
Via Benzinga
Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway'
Piper Sandler assumed coverage of Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight rating and a  
Via Benzinga
Why Ionis Pharmaceutical Shares Are Trading Lower Wednesday
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading lower on Wednesday after the company announced plans to offer $500 million of senior convertible notes due in 2028 in a private placement... 
Via Benzinga
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
The FDA approved Biogen Inc's (NASDAQ: 
Via Benzinga
What's Going On With Biogen Stock Tuesday?
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.  
Via Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
Via Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid. 
Via InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Via Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
This drug candidate could be a great treatment option for patients with a potentially deadly disease. 
Via The Motley Fool
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.